

Lieuwe de Haan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4225253/publications.pdf>

Version: 2024-02-01

180
papers

8,219
citations

76326

40
h-index

60623

81
g-index

187
all docs

187
docs citations

187
times ranked

10428
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	27.8	929
2	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , 2017, 49, 27-35.	21.4	838
3	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. <i>Biological Psychiatry</i> , 2018, 84, 644-654.	1.3	627
4	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. <i>Lancet Psychiatry</i> , 2019, 6, 427-436.	7.4	528
5	Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 149-169.	2.4	294
6	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. <i>JAMA Psychiatry</i> , 2018, 75, 36.	11.0	235
7	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	4.3	229
8	Effect of ω -3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 19.	11.0	216
9	The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. <i>Schizophrenia Research</i> , 2014, 152, 458-468.	2.0	153
10	Trauma and recent life events in individuals at ultra high risk for psychosis: Review and meta-analysis. <i>Schizophrenia Research</i> , 2015, 161, 143-149.	2.0	147
11	Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years. <i>Schizophrenia Bulletin</i> , 2019, 45, 315-329.	4.3	141
12	Ultra high-risk state for psychosis and non-transition: A systematic review. <i>Schizophrenia Research</i> , 2011, 132, 8-17.	2.0	137
13	Early intervention, untreated psychosis and the course of early schizophrenia. <i>British Journal of Psychiatry</i> , 1998, 172, 84-89.	2.8	126
14	The 5-Year Course of Obsessive-Compulsive Symptoms and Obsessive-Compulsive Disorder in First-Episode Schizophrenia and Related Disorders. <i>Schizophrenia Bulletin</i> , 2013, 39, 151-160.	4.3	121
15	Subjective Experience and D ₂ Receptor Occupancy in Patients With Recent-Onset Schizophrenia Treated With Low-Dose Olanzapine or Haloperidol: A Randomized, Double-Blind Study. <i>American Journal of Psychiatry</i> , 2003, 160, 303-309.	7.2	120
16	Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis. <i>Psychiatry Research</i> , 2013, 209, 266-272.	3.3	114
17	Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 547-558.	4.1	96
18	Obsessive-Compulsive Symptoms During Treatment With Olanzapine and Risperidone. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 104-107.	2.2	96

#	ARTICLE	IF	CITATIONS
19	Social Functioning and the Course of Early-Onset Schizophrenia. <i>British Journal of Psychiatry</i> , 2001, 179, 53-58.	2.8	92
20	Psychosis Prediction: Stratification of Risk Estimation With Information-Processing and Premorbid Functioning Variables. <i>Schizophrenia Bulletin</i> , 2014, 40, 1482-1490.	4.3	91
21	Duration of Untreated Psychosis and Outcome of Schizophrenia: Delay in Intensive Psychosocial Treatment Versus Delay in Treatment With Antipsychotic Medication. <i>Schizophrenia Bulletin</i> , 2003, 29, 341-348.	4.3	88
22	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2019, 49, 1378-1391.	4.5	69
23	The Association Between Familial Risk and Brain Abnormalities Is Disease Specific: An ENIGMA-Relatives Study of Schizophrenia and Bipolar Disorder. <i>Biological Psychiatry</i> , 2019, 86, 545-556.	1.3	67
24	In vivo (R)-[11C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis. <i>NPJ Schizophrenia</i> , 2016, 2, 16031.	3.6	63
25	Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review. <i>Drugs</i> , 2017, 77, 1423-1459.	10.9	63
26	Attitudes of Patients Toward the First Psychotic Episode and the Start of Treatment. <i>Schizophrenia Bulletin</i> , 2002, 28, 431-442.	4.3	62
27	Grey Matter Changes Associated with Heavy Cannabis Use: A Longitudinal sMRI Study. <i>PLoS ONE</i> , 2016, 11, e0152482.	2.5	62
28	Subjective Experience and Dopamine D ₂ Receptor Occupancy in Patients Treated with Antipsychotics: Clinical Implications. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 290-296.	1.9	59
29	A state-independent network of depressive, negative and positive symptoms in male patients with schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2018, 193, 232-239.	2.0	58
30	A symptom network structure of the psychosis spectrum. <i>Schizophrenia Research</i> , 2017, 189, 75-83.	2.0	56
31	Obsessive-Compulsive Symptoms and Positive, Negative, and Depressive Symptoms in Patients with Recent-Onset Schizophrenic Disorders. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 519-524.	1.9	55
32	Influence of nursing staff attitudes and characteristics on the use of coercive measures in acute mental health services – A systematic review. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2020, 27, 446-459.	2.1	55
33	Smoking and the risk for bipolar disorder: evidence from a bidirectional Mendelian randomisation study. <i>British Journal of Psychiatry</i> , 2021, 218, 88-94.	2.8	54
34	Evidence for Genetic Overlap Between Schizophrenia and Age at First Birth in Women. <i>JAMA Psychiatry</i> , 2016, 73, 497.	11.0	51
35	Association Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis, Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up Study. <i>American Journal of Psychiatry</i> , 2018, 175, 1121-1128.	7.2	49
36	Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. <i>Schizophrenia Research</i> , 2014, 153, 42-47.	2.0	48

#	ARTICLE	IF	CITATIONS
37	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. <i>Biological Psychiatry</i> , 2020, 87, 243-252.	1.3	48
38	Driving us mad: the association of <i>Toxoplasma gondii</i> with suicide attempts and traffic accidents – a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2019, 49, 1608-1623.	4.5	47
39	Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. <i>Psychopharmacology</i> , 2006, 183, 500-505.	3.1	44
40	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. <i>Biological Psychiatry</i> , 2021, 89, 288-297.	1.3	42
41	Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. <i>Psychopharmacology Bulletin</i> , 2006, 39, 25-30.	0.0	42
42	Presence of obsessive compulsive symptoms in first-episode schizophrenia or related disorders is associated with subjective well-being and quality of life. <i>Microbial Biotechnology</i> , 2013, 7, 285-290.	1.7	41
43	To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. <i>Trials</i> , 2020, 21, 147.	1.6	41
44	The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 645-657.	3.1	41
45	Childhood trauma and clinical outcome in patients at ultra-high risk of transition to psychosis. <i>Schizophrenia Research</i> , 2015, 169, 193-198.	2.0	40
46	Prevalence of Psychotic Disorders in Patients with Obsessive-Compulsive Disorder. <i>CNS Spectrums</i> , 2009, 14, 415-418.	1.2	38
47	Child Maltreatment and Clinical Outcome in Individuals at Ultra-High Risk for Psychosis in the EU-GEI High Risk Study. <i>Schizophrenia Bulletin</i> , 2018, 44, 584-592.	4.3	38
48	Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 1329-1337.	4.5	38
49	Dissociable morphometric profiles of the affective and cognitive dimensions of alexithymia. <i>Cortex</i> , 2014, 54, 190-199.	2.4	35
50	Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 623-633.	4.5	34
51	Transition to first episode psychosis in ultra high risk populations: Does baseline functioning hold the key?. <i>Schizophrenia Research</i> , 2013, 143, 132-137.	2.0	33
52	Medication adherence in patients with schizophrenia: a qualitative study of the patient process in motivational interviewing. <i>BMC Psychiatry</i> , 2018, 18, 135.	2.6	31
53	Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. <i>Journal of Psychopharmacology</i> , 2012, 26, 189-195.	4.0	30
54	Smoking, symptoms, and quality of life in patients with psychosis, siblings, and healthy controls: a prospective, longitudinal cohort study. <i>Lancet Psychiatry</i> , 2019, 6, 25-34.	7.4	30

#	ARTICLE	IF	CITATIONS
55	Interaction of olanzapine with fluvoxamine. <i>Psychopharmacology</i> , 2001, 155, 219-220.	3.1	29
56	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2019, 10, 345.	2.6	29
57	Reliability and Reproducibility of Neuromelanin-sensitive Imaging of the Substantia Nigra: A Comparison of Three Different Sequences. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 712-721.	3.4	29
58	Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis. <i>Journal of Psychopharmacology</i> , 2014, 28, 553-560.	4.0	27
59	Use of Natural Language Processing to identify Obsessive Compulsive Symptoms in patients with schizophrenia, schizoaffective disorder or bipolar disorder. <i>Scientific Reports</i> , 2019, 9, 14146.	3.3	27
60	Emotion processing in schizophrenia is state and trait dependent. <i>Schizophrenia Research</i> , 2015, 161, 392-398.	2.0	26
61	Developmental Trajectories of Impaired Community Functioning in Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 48.	11.0	26
62	Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis. <i>European Neuropsychopharmacology</i> , 2019, 29, 835-846.	0.7	26
63	Specificity of facial emotion recognition impairments in patients with multi-episode schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 12-19.	1.3	25
64	Impact of DSM-5 Changes on the Diagnosis and Acute Treatment of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 637-643.	4.3	24
65	Autistic traits in psychotic disorders: prevalence, familial risk, and impact on social functioning. <i>Psychological Medicine</i> , 2021, 51, 1704-1713.	4.5	24
66	Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. <i>PLoS ONE</i> , 2016, 11, e0159928.	2.5	23
67	The effect of childhood adversity on 4-year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. <i>Psychiatry Research</i> , 2017, 247, 55-62.	3.3	23
68	The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. <i>Journal of Psychopharmacology</i> , 2014, 28, 633-642.	4.0	22
69	COMT Val 158 Met genotype and cannabis use in people with an At Risk Mental State for psychosis: Exploring Gene x Environment interactions. <i>Schizophrenia Research</i> , 2016, 174, 24-28.	2.0	22
70	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. <i>Frontiers in Psychiatry</i> , 2019, 10, 393.	2.6	22
71	Migration history and risk of psychosis: results from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2022, 52, 2972-2984.	4.5	22
72	Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 197-206.	2.4	21

#	ARTICLE	IF	CITATIONS
73	Nursing Staff Factors Contributing to Seclusion in Acute Mental Health Care – An Explorative Cohort Study. <i>Issues in Mental Health Nursing</i> , 2017, 38, 584-589.	1.2	20
74	Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. <i>Schizophrenia Research</i> , 2018, 194, 32-38.	2.0	20
75	Association of <i>Toxoplasma gondii</i> Seropositivity With Cognitive Function in Healthy People. <i>JAMA Psychiatry</i> , 2021, 78, 1103.	11.0	20
76	Treating depressive episodes or symptoms in patients with schizophrenia. <i>CNS Spectrums</i> , 2019, 24, 239-248.	1.2	19
77	Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	19
78	Feasibility of teaching motivational interviewing to parents of young adults with recent-onset schizophrenia and co-occurring cannabis use. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 340-345.	2.8	18
79	Prevalence and correlates of depressive symptoms in a catchment-area based cohort of older community-living schizophrenia patients. <i>Schizophrenia Research</i> , 2014, 157, 285-291.	2.0	18
80	Obsessive-compulsive symptoms and overall psychopathology in psychotic disorders: longitudinal assessment of patients and siblings. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 279-289.	3.2	18
81	Mortality and Its Determinants in Late-Life Schizophrenia: A 5-Year Prospective Study in a Dutch Catchment Area. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 272-277.	1.2	17
82	The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2022, 52, 1376-1385.	4.5	17
83	Changes in peripheral blood compounds following psychopharmacological treatment in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 538-549.	4.5	17
84	Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling. <i>Schizophrenia Research</i> , 2019, 208, 82-89.	2.0	16
85	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. <i>Behaviour Research and Therapy</i> , 2020, 124, 103527.	3.1	16
86	Autistic Symptoms and Social Functioning in Psychosis: A Network Approach. <i>Schizophrenia Bulletin</i> , 2021, , .	4.3	16
87	Advanced Glycation End Products in Recent-Onset Psychosis Indicate Early Onset of Cardiovascular Risk. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1395-1401.	2.2	16
88	Schizophrenia in the Netherlands: Continuity of Care with Better Quality of Care for Less Medical Costs. <i>PLoS ONE</i> , 2016, 11, e0157150.	2.5	15
89	The impact of affective symptoms on personal recovery of patients with severe mental illness. <i>International Journal of Social Psychiatry</i> , 2018, 64, 521-527.	3.1	14
90	Predictors of Adverse Events and Medical Errors Among Adult Inpatients of Psychiatric Units of Acute Care General Hospitals. <i>Psychiatric Services</i> , 2018, 69, 1087-1094.	2.0	14

#	ARTICLE	IF	CITATIONS
91	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 517-529.	4.3	14
92	Active Ingredients and Mechanisms of Change in Motivational Interviewing for Medication Adherence. A Mixed Methods Study of Patient-Therapist Interaction in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 78.	2.6	14
93	Reduced maternal levels of common viruses during pregnancy predict offspring psychosis: Potential role of enhanced maternal immune activity?. <i>Schizophrenia Research</i> , 2015, 166, 248-254.	2.0	13
94	Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series. <i>Journal of Psychopharmacology</i> , 2018, 32, 353-356.	4.0	13
95	Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis. <i>Psychological Medicine</i> , 2023, 53, 2317-2327.	4.5	13
96	Increased prevalence of ECG suspicious for Brugada Syndrome in recent onset schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2019, 210, 59-65.	2.0	12
97	Childhood trauma and coping in patients with psychotic disorders and obsessive-compulsive symptoms and in un-affected siblings. <i>Child Abuse and Neglect</i> , 2020, 99, 104243.	2.6	12
98	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. <i>Translational Psychiatry</i> , 2021, 11, 423.	4.8	12
99	Efficacy of Acceptance and Commitment Therapy in Daily Life in Early Psychosis: Results from the Multi-Center INTERACT Randomized Controlled Trial. <i>Psychotherapy and Psychosomatics</i> , 2022, 91, 411-423.	8.8	12
100	Replicated Evidence of Absence of Association between Serum S100B and (Risk of) Psychotic Disorder. <i>PLoS ONE</i> , 2013, 8, e82535.	2.5	11
101	New Research Strategy for Measuring Pre- and Postnatal Metal Dysregulation in Psychotic Disorders. <i>Schizophrenia Bulletin</i> , 2017, 43, 1153-1157.	4.3	11
102	“But I did not touch nobody!” Patients' and nurses' perspectives and recommendations after aggression on psychiatric wards: A qualitative study. <i>Journal of Advanced Nursing</i> , 2019, 75, 2845-2854.	3.3	11
103	Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 269-279.	1.4	11
104	Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia: An individual patient data meta-analysis. <i>European Neuropsychopharmacology</i> , 2014, 24, 1067-1077.	0.7	10
105	The role of cognitive functioning in the relationship between childhood trauma and a mixed phenotype of affective-anxious-psychotic symptoms in psychotic disorders. <i>Schizophrenia Research</i> , 2018, 192, 262-268.	2.0	10
106	Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1081.	2.4	10
107	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. <i>Schizophrenia Bulletin</i> , 2021, 47, 1018-1028.	4.3	10
108	Grey matter, an endophenotype for schizophrenia? A voxel-based morphometry study in siblings of patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 207-213.	2.4	9

#	ARTICLE	IF	CITATIONS
109	The associations between childhood trauma, neuroticism and comorbid obsessive-compulsive symptoms in patients with psychotic disorders. <i>Psychiatry Research</i> , 2017, 254, 48-53.	3.3	9
110	Accumulation rate of advanced glycation end products in recent onset psychosis: A longitudinal study. <i>Psychiatry Research</i> , 2020, 291, 113192.	3.3	9
111	A comparison of depressive symptom profiles between current major depressive disorder and schizophrenia spectrum disorder. <i>Journal of Psychiatric Research</i> , 2021, 135, 143-151.	3.1	9
112	The Community Assessment of Psychic Experiences: Optimal cut-off scores for detecting individuals with a psychotic disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2021, 30, e1893.	2.1	9
113	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2022, 48, 100-110.	4.3	9
114	Tapering antipsychotic medication: practical considerations. <i>Psychological Medicine</i> , 2022, 52, 32-35.	4.5	9
115	Preliminary validation of a clinical staging model in schizophrenia and related disorders. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, , .	1.4	9
116	Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. <i>Psychological Medicine</i> , 2023, 53, 3396-3405.	4.5	9
117	Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 1104-1114.	4.3	9
118	The Puzzle of Functional Recovery in Schizophrenia-Spectrum Disorders—Replicating a Network Analysis Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 871-880.	4.3	9
119	Economic evaluation of brief cognitive behavioural therapy for social activation in recent-onset psychosis. <i>PLoS ONE</i> , 2018, 13, e0206236.	2.5	8
120	Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 931-940.	3.2	8
121	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. <i>Schizophrenia Research</i> , 2020, 226, 52-60.	2.0	8
122	Association between skin autofluorescence of advanced glycation end products and affective disorders in the lifelines cohort study. <i>Journal of Affective Disorders</i> , 2020, 275, 230-237.	4.1	8
123	Relationship between social cognition, general cognition, and risk for suicide in individuals with a psychotic disorder. <i>Schizophrenia Research</i> , 2021, 231, 227-236.	2.0	8
124	A comparison of indices for identifying the number of clusters in hierarchical clustering: A study on cognition in schizophrenia patients. <i>Communications in Statistics Case Studies Data Analysis and Applications</i> , 2015, 1, 98-113.	0.3	7
125	Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. <i>Psychological Medicine</i> , 2021, 51, 2074-2082.	4.5	7
126	Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study. <i>Psychological Medicine</i> , 2022, 52, 3668-3676.	4.5	7

#	ARTICLE	IF	CITATIONS
127	Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. <i>European Neuropsychopharmacology</i> , 2018, 28, 1024-1034.	0.7	6
128	The relationship between childhood trauma and clinical characteristics in ultra-high risk for psychosis youth. <i>Psychosis</i> , 2019, 11, 28-41.	0.8	6
129	Meta-analysis of cognitive functioning in patients with psychotic disorders and obsessive-compulsive symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 689-706.	3.2	6
130	Medication strategies in first episode psychosis patients: A survey among psychiatrists. <i>Microbial Biotechnology</i> , 2022, 16, 139-146.	1.7	6
131	Cessation of cannabis use by patients with recent-onset schizophrenia and related disorders. <i>Psychopharmacology Bulletin</i> , 2008, 41, 142-53.	0.0	6
132	T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION. <i>Schizophrenia Bulletin</i> , 2018, 44, S132-S133.	4.3	5
133	O5.1. CLOZAPINE AND LONG-TERM MORTALITY RISK IN PATIENTS WITH SCHIZOPHRENIA: PRELIMINARY RESULTS FROM A META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S86-S86.	4.3	5
134	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. <i>Biological Psychiatry</i> , 2019, 85, e35-e39.	1.3	5
135	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 943-952.	3.1	5
136	Insight, personality, and symptoms among individuals with psychosis: Cross-sectional and longitudinal relationships. <i>Schizophrenia Research</i> , 2020, 222, 243-250.	2.0	4
137	Early predictors of mental health in mid-adulthood. <i>Microbial Biotechnology</i> , 2021, 15, 158-166.	1.7	4
138	Greater preference for eveningness is associated with negative symptoms in an ultra-high risk for psychosis sample. <i>Microbial Biotechnology</i> , 2021, 15, 1793-1798.	1.7	4
139	Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1653-1662.	4.3	4
140	Active Ingredients and Mechanisms of Change in Motivational Interviewing for Smoking Cessation in Patients With Coronary Artery Disease: A Mixed Methods Study. <i>Frontiers in Psychology</i> , 2021, 12, 599203.	2.1	4
141	The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. <i>Schizophrenia Research</i> , 2021, 236, 69-79.	2.0	4
142	Momentary Manifestations of Negative Symptoms as Predictors of Clinical Outcomes in People at High Risk for Psychosis: Experience Sampling Study. <i>JMIR Mental Health</i> , 2021, 8, e30309.	3.3	4
143	Machine learning based prediction and the influence of complement Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 50-60.	4.1	4
144	Shortening Duration of Treatment Resistance: The Next Step in the Treatment of Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3

#	ARTICLE	IF	CITATIONS
145	Staging and profiling for schizophrenia spectrum disorders: Inter-rater reliability after a short training course. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109856.	4.8	3
146	Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial. <i>BMC Psychiatry</i> , 2021, 21, 4.	2.6	3
147	Rising co-payments and continuity of healthcare for Dutch patients with bipolar disorder: retrospective longitudinal cohort study. <i>BJPsych Open</i> , 2021, 7, .	0.7	3
148	Viral metagenomics in drug-naïve, first-onset schizophrenia patients with prominent negative symptoms. <i>Psychiatry Research</i> , 2015, 229, 678-684.	3.3	2
149	Stressful experiences affect the course of co-occurring obsessive-compulsive and psychotic symptoms: A focus on within-subject processes. <i>Schizophrenia Research</i> , 2020, 216, 69-76.	2.0	2
150	T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S326-S326.	4.3	2
151	Skin autofluorescence of advanced glycation end products and mortality in affective disorders in the lifelines cohort study: A mediation analysis. <i>Journal of Affective Disorders</i> , 2021, 282, 1082-1089.	4.1	2
152	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. <i>Brain, Behavior, and Immunity</i> , 2022, 99, 147-156.	4.1	2
153	Cross-classified multilevel models improved standard error estimates of covariates in clinical outcomes – a simulation study. <i>Journal of Clinical Epidemiology</i> , 2022, 145, 39-46.	5.0	2
154	Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia. <i>Psychopharmacology</i> , 2017, 234, 3535-3536.	3.1	1
155	F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS. <i>Schizophrenia Bulletin</i> , 2018, 44, S228-S228.	4.3	1
156	O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL. <i>Schizophrenia Bulletin</i> , 2018, 44, S99-S99.	4.3	1
157	F53. DOSE REDUCTION OF HIGH-DOSE FIRST-GENERATION ANTIPSYCHOTICS OR SWITCH TO ZIPRASIDONE IN LONG-STAY PATIENTS WITH SCHIZOPHRENIA: A 1-YEAR DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. <i>Schizophrenia Bulletin</i> , 2018, 44, S239-S240.	4.3	1
158	Patterns of obsessive-compulsive symptoms and social functioning in schizophrenia; a replication study. <i>Psychiatry Research</i> , 2019, 271, 421-427.	3.3	1
159	Skin autofluorescence of advanced glycation end products and course of affective disorders in the lifelines cohort study, a prospective investigation. <i>Journal of Affective Disorders</i> , 2020, 276, 424-432.	4.1	1
160	Reply to interleukin-6 in schizophrenia: Cause of death matters. <i>Brain, Behavior, and Immunity</i> , 2020, 90, 383-384.	4.1	1
161	It might be a wonderful opportunity when patients with a psychotic disorder use cannabis. <i>Psychological Medicine</i> , 2022, 52, 601-602.	4.5	1
162	Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 828376.	2.6	1

#	ARTICLE	IF	CITATIONS
163	Sustained specialized and family treatment in first-episode schizophrenia or related disorders: a 5-year randomized controlled trial. <i>Psychological Medicine</i> , 2023, 53, 4316-4323.	4.5	1
164	Early intervention and the course of recent onset schizophrenia. <i>European Psychiatry</i> , 1998, 13, 144s-144s.	0.2	0
165	School performance in secondary education shows no decline before the onset of a first episode of psychosis in schizophrenia. <i>Journal of Mental Health</i> , 2003, 12, 585-593.	1.9	0
166	Structural MRI Differences between Patients with and without First Rank Symptoms: A Delusion?. <i>Frontiers in Psychiatry</i> , 2015, 6, 107.	2.6	0
167	174.2 Psychosis Prediction: Stratification of Risk Estimation With Information-Processing and Premorbid Functioning Variables. <i>Schizophrenia Bulletin</i> , 2017, 43, S87-S88.	4.3	0
168	O11.3. A LONGITUDINAL ANALYSIS OF THE EFFECTS OF NEUROTICISM AND EXTRAVERSION ON SUBJECTIVE WELL-BEING IN PATIENTS WITH SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S107-S107.	4.3	0
169	The Unhealthy Chicken or the Unhealthy Egg: Quitting Smoking Matters: Response to Hajek et al.. <i>American Journal of Psychiatry</i> , 2019, 176, 575-576.	7.2	0
170	Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531987234.	2.7	0
171	O10.7. SIMILARLY ALTERED PROTEIN MARKERS IN DRUG-NAÏVE FIRST-EPISODE PATIENTS WITH SCHIZOPHRENIA OR MAJOR DEPRESSIVE DISORDER. A META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S192-S193.	4.3	0
172	T68. SUBCLINICAL PSYCHOTIC PHENOMENA ARE ASSOCIATED WITH MARKERS OF AN ALTERED METABOLISM IN A LARGE COMMUNITY SAMPLE. <i>Schizophrenia Bulletin</i> , 2019, 45, S230-S231.	4.3	0
173	Measuring process indicators and adverse events to assess the quality of care for inpatients with psychosis. <i>Journal of Mental Health</i> , 2021, 30, 564-570.	1.9	0
174	T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL. <i>Schizophrenia Bulletin</i> , 2020, 46, S244-S245.	4.3	0
175	S175. CLINICAL OUTCOMES IN PEOPLE AT HIGH RISK FOR PSYCHOSIS RELATED TO INTERACTIONS BETWEEN POLYGENIC RISK SCORES AND CHILDHOOD ADVERSITY. <i>Schizophrenia Bulletin</i> , 2020, 46, S104-S104.	4.3	0
176	S53. DELINEATING SOCIAL COGNITION IN AUTISM AND PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S53-S53.	4.3	0
177	The association between sleep disturbances and negative symptom severity in patients with non-affective psychotic disorders, unaffected siblings and healthy controls. <i>Psychiatry Research</i> , 2021, 297, 113728.	3.3	0
178	Ethnic discrimination and depressed mood: The role of autonomic regulation. <i>Journal of Psychiatric Research</i> , 2021, 144, 110-117.	3.1	0
179	M83. AUTISTIC TRAITS AS LINKING PIN TO SOCIAL FUNCTIONING IN PSYCHOSIS: A NETWORK APPROACH. <i>Schizophrenia Bulletin</i> , 2020, 46, S166-S166.	4.3	0
180	Autistic traits and alcohol use in adolescents within the general population. <i>European Child and Adolescent Psychiatry</i> , 2022, , 1.	4.7	0